Emerging Clinical Strategies in Cholangiocarcinoma: A Review on Targeted Therapy and Immunotherapy
Vanshika Gajjala
21/11/26
Cholangiocarcinoma (CCA) is a rare, highly heterogeneous, and aggressively malignant cluster of biliary tract cancers encompassing intrahepatic, perihilar, and distal subtypes. It disproportionately affects older adults, with roughly 75% of patients diagnosed at the age of 62 or older (Valle et al., 2021), and it is often diagnosed at an advanced, unresectable stage due to its clinically silent onset and deep anatomical seclusion. Five-year survival rates linger below 20%, largely because the foundational standard of care relies heavily on surgical resection and conventional cytotoxic chemotherapy, which has failed to provide durable survival benefits for most late-stage patients.
This review paper summarizes recent changes in the management of CCA. As the field moves from “one-size-fits-all” treatments towards highly personalized, biologically driven interventions, it has become crucial to synthesize the latest advancements in clinical and pre-clinical trials. Evidence was identified through a structured narrative literature search (see Methods) and is labelled by level of evidence throughout. This review compares biomarker-directed therapy with first-line chemoimmunotherapy using the endpoints appropriate to each. In previously treated patients with FGFR2 fusions or rearrangements, FGFR2 inhibitors achieved objective response rates of approximately 35% to 42% in single-arm studies, whereas the IDH1 inhibitor ivosidenib mainly prolonged progression-free survival, with few objective responses. In contrast, the phase III trials TOPAZ-1 and KEYNOTE-966 enrolled broader biliary tract cancer (BTC) populations that included, but were not limited to, CCA, and reported modest overall survival gains with chemoimmunotherapy. Chemoimmunotherapy is now the first-line standard for advanced BTC, whereas biomarker-directed agents are generally used after progression on first-line treatment.
Furthermore, it addresses the limitations hindering these trials, including the logistical challenges of diagnostic tissue acquisition, the rarity of specific genetic cohorts, and the historical practice of pooling distinct anatomical subtypes into single clinical studies. This paper surveys emerging strategies in CCA research by exploring early-phase clinical and preclinical approaches, clearly separated from established evidence, designed to penetrate CCA’s notoriously dense, immunosuppressive desmoplastic stroma. We conclude that further progress in CCA treatment depends on overcoming acquired resistance, democratizing access to comprehensive genomic profiling, and adopting adaptive, molecularly guided clinical trial designs that may extend survival and allow longer-term disease control in selected patients.
